COVID-19 and ICU-acquired MDR Bacteria
COVID-BMR
Impact of SARS-CoV-2 Infection on the Incidence of ICU Acquired Colonization Related to Multidrug-resistant Bacteria
2 other identifiers
observational
368
1 country
7
Brief Summary
This multicenter before-after study aimed to determine the impact of infection related to SARS-CoV-2 on the incidence of ICU-acquired multidrug resistant (MDR) bacteria.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 5, 2020
CompletedFirst Posted
Study publicly available on registry
May 7, 2020
CompletedStudy Start
First participant enrolled
May 18, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 26, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 26, 2021
CompletedApril 22, 2026
October 1, 2022
1.2 years
May 5, 2020
April 17, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cumulative incidence of ICU-acquired colonization related multidrug resistant bacteria
percentage of patients with ICU acquired MDR bacteria colonization
from D3 until day 28 after ICU admission
Secondary Outcomes (4)
Cumulative incidence of ICU-acquired infection related to multidrug resistant bacteria
from D3 until day 28 after ICU admission
Mechanical ventilation duration
from D1 until day 28 after ICU admission
mortality
from D1 until day 28 after ICU admission
length of stay in intensive care unit
from D1 until day 28 after ICU admission
Eligibility Criteria
patients admitted to intensive care
You may qualify if:
- Expected ICU stay \> 48 hours
- Rectal and nasal BMR screening performed \< 48 hours after admission to ICU
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (7)
Chu Amiens Picardie
Amiens, France
Ch Bethune
Béthune, France
Grand Hopital de L'Est Francilien
Jossigny, France
CH LENS
Lens, France
Hôpital Roger Salengro, ICU, CHU Lille
Lille, 59037, France
Hospices Civils de Lyon (Pierre Bénite,Edouard Herriot, La Croix Rousse)
Lyon, France
Hospices Civils de Lyon
Lyon, France
Related Publications (1)
Kreitmann L, Jermoumi S, Vasseur M, Chabani M, Nourry E, Richard JC, Wallet F, Garcon P, Kachmar S, Zerbib Y, Van Grunderbeeck N, Vinsonneau C, Duhamel A, Labreuche J, Nseir S. Relationship between COVID-19 and ICU-acquired colonization and infection related to multidrug-resistant bacteria: a prospective multicenter before-after study. Intensive Care Med. 2023 Jul;49(7):796-807. doi: 10.1007/s00134-023-07109-5. Epub 2023 Jun 16.
PMID: 37326645RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Saad Nseir, MD,PhD
University Hospital, Lille
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 5, 2020
First Posted
May 7, 2020
Study Start
May 18, 2020
Primary Completion
July 26, 2021
Study Completion
July 26, 2021
Last Updated
April 22, 2026
Record last verified: 2022-10